{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:14:02Z","timestamp":1790090042787,"version":"4.0.1"},"reference-count":28,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hallym University Research Fund","award":["HURF-2022-44"],"award-info":[{"award-number":["HURF-2022-44"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>CT83, a cancer-testis antigen, has emerged as a potential biomarker and therapeutic target in various cancers. This study explores its expression and role in cervical adenocarcinoma progression and prognosis. CT83 expression was analyzed in cervical cancer cell lines using quantitative PCR and Western blotting. Functional assays demonstrated that CT83 overexpression (OE) promotes proliferation, migration, invasion, and epithelial\u2013mesenchymal transition (EMT) in cervical cancer cells while also upregulating PD-L1 expression. Conversely, CT83 knockdown reduced these malignant phenotypes. The immunohistochemical analysis of 60 patient samples revealed CT83 expression in 84.9% of cases, with significant correlations to larger tumor size, elevated squamous cell carcinoma antigen (SCC) levels, and advanced FIGO stages (II\u2013IV). Furthermore, intermediate-to-high CT83 expression (H-score \u2265100) was associated with more aggressive disease features. These findings suggest that CT83 contributes to tumor progression and immune evasion, likely through PD-L1 modulation. As a highly expressed antigen in cervical adenocarcinoma, CT83 offers promise as a diagnostic marker and therapeutic target for improving patient outcomes.<\/jats:p>","DOI":"10.3390\/ijms26062687","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T06:36:23Z","timestamp":1742193383000},"page":"2687","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CT83 Promotes Cancer Progression by Upregulation of PDL1 in Adenocarcinoma of the Cervix"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2985-9372","authenticated-orcid":false,"given":"Gilhyang","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Pathology, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul 07441, Republic of Korea"},{"name":"Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Jun","family":"Lee","sequence":"additional","affiliation":[{"name":"Institute of New Frontier Research Team, Hallym University, Chuncheon 24252, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Dongtan Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Kyeonggido 18450, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7841-4532","authenticated-orcid":false,"given":"Sung Taek","family":"Park","sequence":"additional","affiliation":[{"name":"Institute of New Frontier Research Team, Hallym University, Chuncheon 24252, Republic of Korea"},{"name":"Department of Obstetrics and Gynecology, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul 07441, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong Su","family":"Kim","sequence":"additional","affiliation":[{"name":"Institute of New Frontier Research Team, Hallym University, Chuncheon 24252, Republic of Korea"},{"name":"Department of Internal Medicine, Kangnam Sacred-Heart Hospital, Hallym University College of Medicine, Seoul 07441, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5697-8118","authenticated-orcid":false,"given":"Hye-Yon","family":"Cho","sequence":"additional","affiliation":[{"name":"Institute of New Frontier Research Team, Hallym University, Chuncheon 24252, Republic of Korea"},{"name":"Department of Obstetrics and Gynecology, Dongtan Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Kyeonggido 18450, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: A baseline analysis of the WHO Global Cervical Cancer Elimination Initiative","volume":"11","author":"Singh","year":"2023","journal-title":"Lancet Glob. Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ygyno.2014.08.018","article-title":"Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in Gynecologic Oncology Group trials of cisplatin-based chemoradiation","volume":"135","author":"Rose","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/modpathol.2014.55","article-title":"HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases","volume":"27","author":"Pirog","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1034\/j.1600-065X.2002.18803.x","article-title":"Cancer\/testis antigens: An expanding family of targets for cancer immunotherapy","volume":"188","author":"Scanlan","year":"2002","journal-title":"Immunol. Rev."},{"key":"ref_6","first-page":"395","article-title":"Cancer-testis antigens: Potential targets for cancer immunotherapy","volume":"12","author":"Modarressi","year":"2009","journal-title":"Arch. Iran. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"15772","DOI":"10.18632\/oncotarget.4694","article-title":"Oncogenic cancer\/testis antigens: Prime candidates for immunotherapy","volume":"6","author":"Gjerstorff","year":"2015","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ji, J., Chen, J., Wang, A., Zhang, W., Ju, H., Liu, Y., and Li, L. (2021). KK-LC-1 may be an effective prognostic biomarker for gastric cancer. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-07974-7"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kang, Y., Gan, Y., Jiang, Y., You, J., Huang, C., Chen, Q., Xu, X., Chen, F., and Chen, L. (2022). Cancer-testis antigen KK-LC-1 is a potential biomarker associated with immune cell infiltration in lung ade-nocarcinoma. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09930-5"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.21873\/anticanres.12937","article-title":"Detection of KK-LC-1 Protein, a Cancer\/Testis Antigen, in Patients with Breast Cancer","volume":"38","author":"Kondo","year":"2018","journal-title":"Anticancer. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12967-024-04918-0","article-title":"Cancer testis antigen burden (CTAB): A novel biomarker of tumor-associated antigens in lung cancer","volume":"22","author":"Seager","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s40425-019-0678-x","article-title":"Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung Cancer Antigen-1","volume":"7","author":"Marcinkowski","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1126\/science.aak9510","article-title":"Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer","volume":"356","author":"Pasetto","year":"2017","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"TPS2678","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS2678","article-title":"A phase I trial of T-cell receptor gene therapy targeting KK-LC-1 for gastric, breast, cervical, lung and other KK-LC-1 positive epithelial cancers","volume":"40","author":"Norberg","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Rotman, J., Otter, L.A.S.D., Bleeker, M.C.G., Samuels, S.S., Heeren, A.M., Roemer, M.G.M., Kenter, G.G., Zijlmans, H.J.M.A.A., van Trommel, N.E., and de Gruijl, T.D. (2020). PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.596825"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wang, Y., Wang, H., Yao, H., Li, C., Fang, J.-Y., and Xu, J. (2018). Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00536"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/08820139.2016.1197241","article-title":"Cancer\/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers","volume":"45","author":"Salmaninejad","year":"2016","journal-title":"Immunol. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.trecan.2018.08.005","article-title":"Emerging Contributions of Cancer\/Testis Antigens to Neoplastic Behaviors","volume":"4","author":"Gibbs","year":"2018","journal-title":"Trends Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e12581","DOI":"10.1111\/cpr.12581","article-title":"Hypomethylation-mediated activation of cancer\/testis antigen KK-LC-1 facilitates hepatocellular carcinoma progression through activating the Notch1\/Hes1 signalling","volume":"52","author":"Chen","year":"2019","journal-title":"Cell Prolif."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in Patients With Microsatellite Instability\u2013High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study","volume":"40","author":"Bariani","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11397","DOI":"10.1007\/s00432-023-05020-6","article-title":"Comparison of PD-L1 expression and MMR status between primary and matched metastatic lesions in patients with cervical cancer","volume":"149","author":"Liu","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.2147\/CMAR.S194597","article-title":"Expression of PD-L1 in cervical carcinoma and its impact on survival associated with T-cell infiltration and FoxP3 expression","volume":"11","author":"Grochot","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/PAS.0000000000001633","article-title":"PD-L1 Expression in Endocervical Adenocarcinoma: Correlation With Patterns of Tumor Invasion, CD8+ Tumor-infiltrating Lymphocytes, and Clinical Outcomes","volume":"45","author":"Chen","year":"2021","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10376","DOI":"10.1111\/jcmm.16967","article-title":"Cancer testis antigen PRAME: An anti-cancer target with immunomodulatory potential","volume":"25","author":"Naik","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e006555","DOI":"10.1136\/jitc-2022-006555","article-title":"Addressing resistance to PD-1\/PD-(L)1 pathway inhibition: Considerations for combinatorial clinical trial designs","volume":"11","author":"Zhang","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Fukuyama, T., Futawatari, N., Yamamura, R., Yamazaki, T., Ichiki, Y., Ema, A., Ushiku, H., Nishi, Y., Takahashi, Y., and Otsuka, T. (2018). Expression of KK-LC-1, a cancer\/testis antigen, at non-tumour sites of the stomach carrying a tumour. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-24514-9"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/6\/2687\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:54:53Z","timestamp":1760028893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/6\/2687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["ijms26062687"],"URL":"https:\/\/doi.org\/10.3390\/ijms26062687","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]}}}